Finance

Lists
UNCY:NASDAQ
Unicycive Therapeutics Inc
$5.07
-2.50%
(-0.13) 1D
Sep 1, 12:24:21 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for UNCY...
Open
$5.13
High
$5.21
Low
$5.04
Mkt. cap
141.23M
Avg. vol.
753.53K
Volume
359.30K
52-wk high
$8.74
52-wk low
$3.72
EPS
-$1.62
Beta
1.79
Shares outstanding
27.86M
No. of employees
22
Open
$5.13
High
$5.21
Low
$5.04
Mkt. cap
141.23M
Avg. vol.
753.53K
Volume
359.30K
52-wk high
$8.74
52-wk low
$3.72
EPS
-$1.62
Beta
1.79
Shares outstanding
27.86M
No. of employees
22
News stories
From web sources and news partners
About Unicycive Therapeutics Inc
CEO-
Employees22
Founded2016
Headquarters-
SectorBiotechnology
Analyst ratings
Based on 6 analysts giving stock ratings to UNCY in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for UNCY in the last 3 months.
Highest
Current $5.07
$50.00 (+886.19%)
Average
$25.83 (+409.47%)
Lowest
$15.00 (+195.86%)
Analyst
Recommendation
Action
Price target
Projected
Date
Bruce Jackson
Benchmark Co.
Buy
Maintained
$15.00
+195.9%
08/20/2026
Jason McCarthy
Maxim Group
Buy
Maintained
$30.00
+491.7%
08/17/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
$20.00
+294.5%
08/13/2026
Robert LeBoyer
Noble Financial
Buy
Reiterated
$50.00
+886.2%
08/13/2026
Vamil Divan
Guggenheim
Buy
Maintained
$25.00
+393.1%
08/12/2026
Swayampakula Ramakanth
H.C. Wainwright
Buy
Maintained
$15.00
+195.9%
08/13/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$90.00
+1,675.1%
06/01/2026
Unknown Analyst
Westpark Capital
Buy
Initiated
$72.00
+1,320.1%
02/19/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
2.96M
2.25M
1.61M
2.79M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.38M
4.97M
6.83M
7.35M
Operating expense
7.34M
7.22M
8.44M
10.14M
Total operating expenses
7.34M
7.22M
8.44M
10.14M
Operating income
-7.34M
-7.22M
-8.44M
-10.14M
Other non operating income
1.07M
-7.77M
-4.78M
7.98M
EBT including unusual items
-6.01M
-14.67M
-12.82M
-1.72M
EBT excluding unusual items
-6.01M
-14.67M
-12.82M
-1.72M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-6.01M
-14.67M
-12.82M
-1.72M
Net profit margin
-
-
-
-
Earnings per share
-0.33
-0.82
-0.54
-0.06
Interest and investment income
279.00K
351.00K
394.00K
441.00K
Interest expense
-15.00K
-27.00K
-
-
Net interest expenses
264.00K
324.00K
394.00K
441.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-7.33M
-7.21M
-8.43M
-10.13M
Gain or loss from assets sale
-
-
18.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
AI content may include mistakes. Learn more
Google apps